Treatment of headache using anti-CGRP antibodies
Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.
1. A method of immediate treatment and relief of migraine headache, comprising intravenously administering to a patient in need thereof an effective amount of an anti-Calcitonin Gene Related Peptide (CGRP) antibody while the patient is experiencing a headache associated with an attack of migraine, wherein said anti-CGRP antibody is a full-length IgG antibody which comprises: the light chain complementarity determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224, SEQ ID NO: 226, and SEQ ID NO: 228, respectively; and heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204, SEQ ID NO: 206, and SEQ ID NO: 208, respectively; wherein the intravenous administration begins within 1-6 hours of the onset of said migraine headache.
2. The method of claim 1 , wherein the intravenously administered amount of said anti-CGRP antibody is between about 100 mg and about 300 mg.
3. The method of claim 1 , wherein the intravenously administered amount of said anti-CGRP antibody is about 100 mg.
4. The method of claim 1 , wherein the intravenously administered amount of said anti-CGRP antibody is about 300 mg.
5. The method of claim 1 , wherein said anti-CGRP antibody comprises the variable light chain polypeptide of SEQ ID NO: 222 and the variable heavy chain polypeptide of SEQ ID NO: 202.
6. The method of claim 1 , wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201.
7. The method of claim 3 , wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201.
8. A method for treatment of migraine in a patient in the need of rapid relief of migraine, comprising intravenously administering to a patient in need thereof 100 or 300 mg of an anti-Calcitonin Gene Related Peptide (CGRP) antibody while the patient is exhibiting headache and at least one migraine symptom during a migraine attack, wherein said anti-CGRP antibody is a full-length IgG antibody which comprises: the light chain complementarity determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224, SEQ ID NO: 226, and SEQ ID NO: 228, respectively; and heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204, SEQ ID NO: 206, and SEQ ID NO: 208, respectively; wherein the intravenous administration begins between 1-6 hours after the onset of said migraine attack.
9. The method of claim 8 , wherein the intravenously administered amount of said anti-CGRP antibody is 100 mg.
10. The method of claim 8 , wherein the intravenously administered amount of said anti-CGRP antibody is 300 mg.
11. The method of claim 8 , wherein the at least one migraine symptom comprises a most bothersome symptom selected from nausea, photophobia, and phonophobia, and wherein the most bothersome symptom is alleviated within 12 hours, within 6 hours, within 5 hours, within 4 hours, within 3 hours, within 2 hours, within 1 hour, or within 30 minutes after the administering.
12. The method of claim 8 , wherein said anti-CGRP antibody comprises the variable light chain polypeptide of SEQ ID NO: 222 and the variable heavy chain polypeptide of SEQ ID NO: 202.
13. The method of claim 8 , wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201.
14. The method of claim 9 , wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201.
15. The method of claim 10 , wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201.